TAS-102 and bevacizumab for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with advanced colorectal cancer who are unable to receive standard combination chemotherapy. It tests a combination of two drugs, TAS-102 and bevacizumab, as the first treatment for their condition. The goal is to see if this combination can help slow the growth of the cancer and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have colorectal cancer with spread (metastatic disease)
- You have not yet had chemotherapy or targeted therapy for advanced disease, or if you did have adjuvant therapy after surgery, it was completed at least 12 months ago
- You cannot tolerate or prefer not to receive standard combination chemotherapy
- You are in reasonably good health (able to care for yourself)
- Your liver, kidney, and blood test results are within the ranges required by the study
- You are willing to use effective birth control during and for 6 months after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.